Peptogenic — Research Materials, Verified.
PeptidesWeight & Metabolic

Metabolic

Retatrutide

Triple agonist of GLP-1, GIP and Glucagon receptors

Verify product Dosage calculator
  • COA per lot · Verified
  • HPLC tested · ≥99%
  • Lab verified purity
Retatrutide — research vial with certificate of analysis
Purity
≥99%
Half-life
≈6 days
Mol. wt
≈4,731 Da
Format
40 mg pre-filled pen
Storage
Refrigerate 2–8°C. Protect from light.
Category
Metabolic

Research profile

Key research benefits

  • Investigated for significant reductions in body weight
  • Improvements in glycemic and lipid markers reported in trials
  • Once-weekly dosing profile owing to ≈6-day half-life
  • Triple-receptor mechanism unique in the GLP-1 class

Retatrutide is an investigational triple receptor agonist studied for its effects on metabolic regulation, body composition and glycemic control in preclinical and Phase-2 clinical research.

Simultaneous agonism of GLP-1, GIP and glucagon receptors modulates satiety, gastric emptying and hepatic glucose output while raising basal energy expenditure — a mechanistic combination not previously available in a single molecule.

Phase-2 data (Jastreboff et al., NEJM 2023) reported dose-dependent body-weight reduction of up to 24% over 48 weeks alongside improvements in HbA1c and lipid markers in adult participants.

  • Obesity and body-composition research
  • Type-2 diabetes and glucose-handling studies
  • Cardiometabolic risk-factor research

PeriodDoseUnits (U-100)
Week 1–42 mg15 units
Week 5–84 mg30 units
Week 9–126 mg45 units
Week 13+8 mg60 units

Adjust dose based on study design and tolerability. Consult your protocol.

For research use only. Not for human or veterinary consumption. Not FDA-approved for the treatment or prevention of any disease.